Zheng Quan Shi Bao Wang·2025-10-31 10:02Core Viewpoint - The concept of generic drug consistency evaluation has seen a significant increase, with a rise of 3.31% as of the market close on October 31, ranking it seventh among concept sectors [1]. Group 1: Market Performance - Within the generic drug consistency evaluation sector, 135 stocks experienced gains, with notable performers including Zhongsheng Pharmaceutical, Lianhuan Pharmaceutical, and Haishike, all reaching their daily limit up [1]. - The top gainers in this sector were Kangzhi Pharmaceutical, Deyuan Pharmaceutical, and Yuandong Biological, with increases of 17.47%, 13.09%, and 11.45% respectively [1]. - Conversely, Shanghai Pharmaceuticals, *ST Suwu, and Jianfeng Group were among the top decliners, with decreases of 2.07%, 1.98%, and 1.81% respectively [1]. Group 2: Capital Inflow - The generic drug consistency evaluation sector attracted a net inflow of 2.434 billion yuan, with 72 stocks receiving net inflows, and 8 stocks exceeding 100 million yuan in net inflow [2]. - The leading stock in terms of net capital inflow was Yongtai Technology, which saw a net inflow of 397 million yuan, followed by Lianhuan Pharmaceutical and Zhongsheng Pharmaceutical with net inflows of 349 million yuan and 305 million yuan respectively [2]. Group 3: Capital Flow Ratios - Lianhuan Pharmaceutical, Anglikang, and Yatai Pharmaceutical had the highest capital inflow ratios, with net inflow rates of 41.17%, 33.00%, and 21.24% respectively [3]. - The top stocks in the generic drug consistency evaluation sector based on capital inflow included Yongtai Technology, Lianhuan Pharmaceutical, and Zhongsheng Pharmaceutical, with respective daily gains of 6.16%, 10.01%, and 10.02% [3].